Vistagen Therapeutics (VTGN) Change in Acquisitions & Divestments (2024 - 2026)

Vistagen Therapeutics has reported Change in Acquisitions & Divestments for 3 years, with the latest figure at $5.6 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 23.07% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.6 million (up 79.39% YoY) and the FY2026 annual result came in at $21.6 million, up 79.39% from the prior year.
• Change in Acquisitions & Divestments slipped to $5.6 million in Q1 2026 per VTGN's latest filing, from $6.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $8.0 million in Q2 2025 and troughed at $2.0 million in Q4 2024.
• A 3-year average of $4.8 million and a median of $5.5 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The widest YoY moves for Change in Acquisitions & Divestments: up 200.15% in 2025, down 63.62% in 2025.
• Over 3 years, Change in Acquisitions & Divestments stood at $2.0 million in 2024, then soared by 200.15% to $6.0 million in 2025, then dropped by 7.08% to $5.6 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $5.6 million, $6.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.